sergign-shutterstock-com
sergign / Shutterstock.com
17 November 2015Big Pharma

Celgene fends off Kyle Bass challenge

Biopharmaceutical company Celgene has finally found success in fending off a challenge to one of its patents fr om Kyle Bass’s organisation the Coalition for Affordable Drugs.

The coalition sought the revocation of Celgene’s US patent 5,635,517 in an inter partes review (IPR) petition filed at the Patent Trial and Appeal Board (PTAB).

The patent covers a method of decreasing the level of tumour necrosis factor. The patent covers Celgene’s drug Pomalyst (pomalidomide).

Yesterday, November 16, the PTAB said there was not a “reasonable likelihood that it would prevail at trial” and rejected the coalition’s IPR petition.

It is the first success for Celgene in its battle with the coalition at the PTAB.

Last month, a three-judge panel instituted an IPR against two patents covering its Revlimid (lenalidomide) drug.

Celgene had asked the PTAB to sanction the coalition and Bass for allegedly abusing the IPR process.

The PTAB dismissed Celgene’s motion in September.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
28 October 2015   The Coalition for Affordable Drugs, an organisation closely tied to hedge fund manager Kyle Bass, has persuaded the Patent Trial and Appeal Board to institute an inter partes review concerning the validity of two patents owned by biopharmaceutical company Celgene.
Americas
24 February 2016   Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another.
Americas
25 February 2016   The Coalition for Affordable Drugs and Anacor Pharmaceuticals will face off in a dispute over the validity of two anti-fungal patents after the Patent Trial and Appeal Board gave the go-ahead to two inter partes review petitions.

More on this story

Americas
28 October 2015   The Coalition for Affordable Drugs, an organisation closely tied to hedge fund manager Kyle Bass, has persuaded the Patent Trial and Appeal Board to institute an inter partes review concerning the validity of two patents owned by biopharmaceutical company Celgene.
Americas
24 February 2016   Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another.
Americas
25 February 2016   The Coalition for Affordable Drugs and Anacor Pharmaceuticals will face off in a dispute over the validity of two anti-fungal patents after the Patent Trial and Appeal Board gave the go-ahead to two inter partes review petitions.

More on this story

Americas
28 October 2015   The Coalition for Affordable Drugs, an organisation closely tied to hedge fund manager Kyle Bass, has persuaded the Patent Trial and Appeal Board to institute an inter partes review concerning the validity of two patents owned by biopharmaceutical company Celgene.
Americas
24 February 2016   Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another.
Americas
25 February 2016   The Coalition for Affordable Drugs and Anacor Pharmaceuticals will face off in a dispute over the validity of two anti-fungal patents after the Patent Trial and Appeal Board gave the go-ahead to two inter partes review petitions.